Saturday 17 October 2026
Export EIGRQ’s income statement to Excel — free account
Eiger BioPharmaceuticals, Inc.
EIGRQ Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022. Revenue growth for three consecutive years, operating cash flow growth for three.
8.50
0.00
0.00%
Follow EIGRQ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 4 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 14.49 | 3.83 | 0.66 |
Altman Z-Score |
— | — | — | — | — | (3.03) | (6.15) | (24.53) |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (7.65) | (11.11) | (58.32) |
P/Operating CF |
— | — | — | — | — | (10.50) | (2.32) | (0.75) |
Beneish M-Score |
— | — | — | — | — | — | (3.67) | (3.24) |
P/B ratio |
— | — | — | — | — | 2.43 | 0.93 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | 2.43 | 0.93 | 0.00 |
EV/Sales |
— | — | — | — | — | 9.80 | (0.53) | 4.24 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.08 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (1.67) | 0.09 | (0.90) |
EV/FCF |
— | — | — | — | — | (1.67) | 0.09 | (0.90) |
Quick Ratio |
11.33 | 5.75 | 10.01 | 5.60 | 7.75 | 3.06 | 4.01 | 0.51 |
Current Ratio |
11.44 | 5.85 | 10.16 | 5.92 | 8.29 | 3.46 | 4.68 | 0.71 |
Net Debt/EBITDA |
0.98 | 0.64 | 1.45 | 0.93 | 1.58 | 0.76 | 0.64 | (0.22) |
Debt/Assets |
24.25% | 35.20% | 25.01% | 29.41% | 22.13% | 25.15% | 33.39% | 105.91% |
Debt/Equity |
0.36 | 0.67 | 0.38 | 0.55 | 0.33 | 0.44 | 0.73 | (2.84) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.11 | 0.20 |
Operating CF/Net income |
0.81 | 0.90 | 0.81 | 0.91 | 0.97 | 2.10 | 0.86 | 0.99 |
Capex/Depreciation |
3.22 | (13.00) | 0.38 | (25.00) | (0.34) | (0.13) | (0.35) | 0.28 |
Interest Coverage |
(66.84) | (27.24) | (21.92) | (20.23) | (17.29) | (21.62) | (22.44) | (13.13) |
| (724.30%) | (134.24%) | (117.58%) | (114.16%) | (85.87%) | (40.51%) | (151.56%) | (367.00%) | |
| (142.00%) | (81.93%) | (72.10%) | (67.68%) | (52.31%) | (25.12%) | (78.51%) | (94.31%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (312.68%) | 0.00% | (3,674.55%) |
Return on Tangible Assets |
(85.14%) | (120.25%) | (56.95%) | (83.61%) | (53.37%) | (45.79%) | (103.94%) | 505.89% |
Average Days of Receivables |
— | — | — | — | — | 77.44 | 47.34 | 38.92 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 530.69% | 558.31% | 395.18% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 196.84% | 215.85% | 159.79% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 65.07% | 61.68% | 31.75% |
Graham Net Nets |
— | — | — | — | — | 0.28 | 1.02 | (1.48) |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 106.11 |
Earnings Yield |
— | — | — | — | — | (19.29%) | (188.90%) | (723.58%) |
Free Cash Flow Yield |
— | — | — | — | — | (40.55%) | (161.30%) | (715.72%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.74 | 9.71 | 10.69 |
Operating CF per Share |
(189.85) | (132.04) | (93.99) | (83.83) | (67.42) | (63.12) | (59.81) | (50.51) |
Capex per Share |
(0.29) | 0.54 | (0.31) | (0.63) | (0.28) | (0.20) | (0.24) | (0.16) |
Free Cash Flow per Share |
(190.14) | (131.51) | (94.30) | (84.46) | (67.69) | (63.32) | (60.05) | (50.67) |
Cash per Share |
299.68 | 143.77 | 221.04 | 125.19 | 137.47 | 78.58 | 71.29 | 17.24 |
Shareholders Equity per Share |
203.61 | 77.50 | 146.68 | 74.43 | 101.40 | 64.05 | 39.85 | (9.80) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
203.61 | 77.50 | 146.68 | 74.43 | 101.40 | 64.05 | 39.85 | (9.80) |
Free Cash Flow |
(38.03) | (38.22) | (42.81) | (64.09) | (63.44) | (71.57) | (83.35) | (74.78) |
Working Capital |
55.23 | 35.22 | 91.82 | 83.44 | 121.18 | 73.46 | 92.41 | (15.44) |
Capital Expenditures |
(0.06) | 0.16 | (0.14) | (0.47) | (0.26) | (0.22) | (0.34) | (0.23) |
Net Current Asset Value |
40.50 | 22.13 | 65.99 | 51.73 | 89.25 | 49.36 | 52.71 | (15.44) |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.08 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.01 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
(0.24) | (0.15) | (2.23) | 0.03 | 1.08 | 2.93 | 1.40 | (1.33) |
Cash ROIC |
(32.96%) | (48.13%) | (22.23%) | (35.14%) | (24.82%) | (37.08%) | (42.88%) | (143.53%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 6.24 | 9.19 |
Accounts Payable Turnover |
0.01 | 0.01 | 0.01 | 0.08 | 0.12 | 0.12 | 0.22 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.55 | 0.67 | 0.01 |
Average Days of Payables |
41,879.78 | 28,336.46 | 39,406.48 | 4,817.10 | 2,625.74 | 3,804.33 | 1,783.27 | 32,165.63 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 52.63 | 1,279.70 | 566.87 | 23,664.17 |
Average Receivables |
— | — | — | — | — | — | 2.16 | 1.72 |
Average Payables |
2.29 | 2.91 | 4.51 | 6.12 | 5.53 | 6.20 | 8.37 | 5.55 |
Average Inventory |
— | — | — | — | 1.35 | 1.35 | 2.73 | 2.20 |
Average Assets |
33.16 | 51.81 | 72.67 | 103.79 | 124.37 | 135.00 | 123.27 | 79.48 |
Average Common Equity |
6.50 | 31.62 | 44.56 | 61.54 | 75.76 | 83.72 | 63.85 | 20.43 |
Columns are period end dates